Medicine and Dentistry
Abiraterone Acetate
14%
Analysis
9%
Androgen
26%
Androgen Deprivation Therapy
13%
Androgen Receptor
18%
Androgen Synthesis
5%
Castration Resistant Prostate Cancer
49%
Chemotherapy
12%
Clinical Trial
11%
Combination Therapy
29%
Consensus
9%
Development
9%
Diagnosis
5%
Disease
17%
Disease Exacerbation
6%
Docetaxel
7%
Hormone
6%
Hormone Therapy
11%
Inpatient
25%
Malignant Neoplasm
8%
Man
17%
Metastatic Carcinoma
11%
Neoplasm
9%
Overall Survival
12%
Patient
78%
Prednisone
8%
Prostate Cancer
100%
Prostate Specific Antigen
23%
Serum
5%
Survival
8%
Testosterone
6%
Therapeutic Procedure
38%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
17%
Abiraterone Acetate
39%
Adverse Event
8%
Androgen
38%
Androgen Receptor
19%
Antitumor Activity
5%
Biological Marker
6%
Castration Resistant Prostate Cancer
81%
Chemotherapy
19%
Clinical Trial
6%
Disease Exacerbation
8%
Diseases
14%
Docetaxel
25%
Enzalutamide
5%
Hormone
8%
Ketoconazole
6%
Malignant Neoplasm
7%
Metastasis
6%
Neoplasm
8%
Overall Survival
20%
Prednisone
32%
Progression Free Survival
11%
Prostate Cancer
61%
Prostate Specific Antigen
28%
Survival
9%
Testosterone
5%
Toxicity
11%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
19%
BRCA2
5%
Clinical Trial
8%
Development
7%
Enzalutamide
5%
Mutation
11%
Nested Gene
8%
Overall Survival
10%
Prednisone
9%
Prostate-Specific Antigen
11%
Survival
5%
Testosterone
6%
Time
5%